Wanlu Medical Secures Bid in Beijing-Tianjin-Hebei '3+N' Alliance Procurement, Demonstrating Full Control Over Vascular Intervention Technology and Manufacturing Chain

NeurointerventionThe surgery is renowned for its minimal invasiveness, excellent efficacy, high efficiency, and significant potential for development.Resolved many clinical challenges,Hailed as the “Crown Jewel” of Interventional Procedures, particularly demonstrating significant advantages in the management of acute cardiovascular and cerebrovascular emergencies, enabling precise treatment within the golden time window and effectively reducing mortality and disability rates.

Taking stroke, the primary indication for neurointerventional procedures, as an example, according to data from the "China Stroke Prevention and Treatment Report (2023),"In China, the number of prevalent stroke cases among individuals aged 40 and above has reached 12.42 million, ranking first globally, with a trend toward younger onset ages.In China, one person experiences an initial or recurrent stroke every 10 seconds on average, and one person dies from stroke every 28 seconds. Among survivors, approximately 75% are left with sequelae, and 40% suffer from severe disability, imposing substantial economic burdens as well as physical and psychological distress on patients’ families.

Driven by patient demand, China’s neurointerventional market reached approximately RMB 14.3 billion in 2023 and is projected to grow to RMB 48.9 billion by 2030, according to research data from Frost & Sullivan. Although neurointerventional techniques have opened up new avenues and therapeutic approaches for cerebrovascular diseases such as stroke, the tortuous and complex anatomy of cerebral vessels makes actual interventional procedures highly challenging, thereby imposing higher requirements on physicians’ technical skills and surgical devices.

Among these, neurointerventional microguidewires represent another challenging device, demanding exceptional flexibility and maneuverability to accurately reach lesion sites while navigating complex cerebral vascular networks. The design and manufacturing of microguidewires are extremely difficult, requiring high precision and advanced materials science. Their R&D and production standards directly impact surgical success rates and patient prognosis.

Vanroo Medical (Jiangsu) Technology Co., Ltd. (hereinafter referred to as “Vanroo Medical”) is an innovative medical technology company focused on the treatment of vascular diseases. The company is dedicated to the research, development, and sales of vascular interventional medical devices. Equipped with large-scale GMP-compliant workshops and biochemistry laboratories, it has achieved 100% independent research and development of core equipment for its production lines, enabling comprehensive manufacturing and quality inspection of its full range of devices. Currently, the company is rapidly advancing industrialization, achieving continuous technological breakthroughs, and has successfully launched multiple products into the market.

Among neurovascular interventional medical devices, guidewires are among the most technically challenging products and command the highest level of physician reliance. As the initial access pathway, guidewires directly determine whether subsequent therapeutic procedures can be carried out smoothly.Vanroo Medical, established in 2020, currently has three core catheter products on the market: Mei Yu Jian^®️Micro-guidewire and Chudongjiao^®️Delivery catheter, and Tiediexian, which was approved for market launch in March 2024^®️Microguidewire.

Xiao Disheng, Founder and CEO of Vanroo MedicalIntroduced as “Featherless Arrow”^®️, Cave-Dwelling Jiao^®️These three names, including Tie Di Xian®, are all derived from the classic Chinese novel Water Margin. The purpose of naming them after heroic nicknames is to reflect the team’s meticulous craftsmanship, ensuring that each product possesses unique performance characteristics and advantages. This approach aims to meet the operational needs of clinicians while better serving patients, and it also demonstrates the confidence to showcase the power of China’s original innovation to the world.

Micro-guidewires are interventional devices inserted into microcatheters to provide guidance and support. Selecting the appropriate guidewire is particularly critical during surgical procedures.Featherless Arrow^®️The micro-guidewire received its Class III medical device registration certificate from the NMPA in 2022. It is a multifunctional, innovative guidewire that integrates maneuverability and durability, designed for distal vascular interventions to optimize thrombectomy procedures and device exchange, particularly during vascular device exchanges.

Featherless Arrow^®️Micro-guidewire

Specifically, Meiyujian^®Its unique innovation is mainly reflected in materials and performance.Featherless Arrow^®️Replaced traditional stainless steel coil springs and hypotubes with novel TPU tubing., while retaining the platinum-tungsten alloy coil tip, enhances guidewire support and torque performance after core wire heat shrinking, maintaining distal softness,The distal torque ratio is close to 1:1.

Meiyujian^®️It also employs a proprietary nitinol-stainless steel joining technology., while abandoning traditional nitinol/stainless steel welding technology, it combines the strong support of stainless steel with the shape-memory properties of nitinol alloy. The resulting advantages are reflected in Mei Yu Jian^®️The distal tip is softer, maximizing the guidewire's torque control and enabling it to maintain its shape more effectively when navigating tortuous vessels. Mei Yu Jian^®️The stiffer distal end provides excellent support.

Meanwhile, Mei Yu Jian^®️The hydrophilic coating on the inner wall also demonstrates excellent performance, ensuring smooth advancement and retraction of the guidewire within both the catheter system and the vasculature, while enhancing durability.Furthermore, based on the characteristics of neurovascular interventional procedures, Meiyujian^®️The distal tip is available in both soft and standard (stiff) configurations, catering to the diverse therapeutic needs of hemorrhagic and ischemic lesions, respectively.

Iron Flute Immortal^®️Steerable Guidewire is an integrated steerable micro-guidewire, particularly suitable for procedures involving hemorrhagic diseases, especially in the treatment of aneurysms.The most prominent advantage of this product lies in its adoption of a high-support stainless steel core wire grinding technology, as opposed to traditional nitinol-stainless steel spliced guidewires. This design endows the guidewire with superior torque control, thereby enhancing procedural safety and guidewire stability. Furthermore, this guidewire is the first to be developed using the novel DTX guidewire R&D platform, which incorporates numerous new technologies to deliver exceptional cost-effectiveness for micro-guidewires.

Iron Flute Immortal^®️08/14 Steerable Guidewire

Optimized for the DTX Platform, Tie Di Xian^®️The shaping performance of the guidewire tip has been significantly improved; the hydrophilic coating on the metallic tip enhances its deliverability and safety profile.This guidewire is a true aneurysm treatment guidewire, aligning with Vanroo Medical’s innovative R&D philosophy of developing specialized guidewires tailored to different medical conditions.

“Adhering to original research and development rather than homogenization is the founding principle that Vanroo Medical upholds as an innovative enterprise. Through collaborative innovation within its team, in the futureVanroo Medical alsoSeveral innovative guidewires tailored for various indications are poised to receive regulatory approval and enter the market, better meeting the demands of interventional surgical treatment for cerebrovascular diseases.”Xiao DishengSpeaking of.

After more than four years of accumulation, Vanroo Medical has currently completed the research and development and reserve of multiple core technologies, such as advanced technology platforms including the CTX high-precision tubing extrusion technology platform, DTX guidewire technology platform, steerable tip technology, vascular drifting magnetic attraction technology, and biodegradable material technology.

“Overall, Vanroo Medical’s foundational technological innovations are primarily concentrated in two key areas: materials and manufacturing processes. In the field of high-end vascular interventional medical devices, advancements and innovations in production processes and manufacturing equipment are just as critical as technological innovation. Many Chinese manufacturers often limit themselves to imitating foreign technical pathways and hesitate to adopt new materials and processes. However, in the long run, only by achieving 100% autonomous control over products and production technologies, thereby seizing the initiative in innovation, can China robustly and sustainably drive the advancement of its high-end medical device industry,” said Xiao Disheng.

According to reports, Vanroo Medical’s high-precision tubing extrusion technology platform was independently developed by its team. It meets all current requirements for ultra-thin-walled tubing extrusion and supports the production of complex multi-lumen, co-extruded, corrugated, and other irregularly shaped tubular products. Furthermore, the Vanroo team has independently developed a range of modified materials with low friction, antibacterial, and anticoagulant properties tailored for different scenarios, thereby broadening their applicability in the field of vascular intervention. Meanwhile, to further enhance cost-effectiveness, the company employs an advanced thermal rheology system (with multi-segment continuity) to minimize material waste and achieve cost reduction.

Vanroo Medical’s in-house developed braiding and coiling technologies are specifically categorized into two major processes and their combinations—vertical continuous braiding and precision horizontal mandrel braiding, as well as coil-braid hybrid structures. Meanwhile, the company’s braiding and spring-coiling equipment are all independently researched, designed, and manufactured in-house, enabling the extensive braiding of reinforcement materials including stainless steel, Nitinol, nylon monofilament, Kevlar, and other specialty polymers.

Vanroo Medical's Self-Developed Braiding Equipment

In addition to the two major technology platforms mentioned above,Vanroo Medical also possesses a biochemistry laboratory and testing platform compliant with ISO 13485 certification, capable of supporting process inspection, leak testing, tensile strength testing, and other validation tests required by NMPA regulations.

Biochemistry Laboratory & Testing Platform

As a leading provider of advanced diagnostics and therapeutics specializing in novel endovascular solutions and drug-device combination therapies for cerebral aneurysms,To further elevate nursing standards and improve treatment success rates in vascular interventional therapy, Vanroo Medical is developing steerable catheter technology, magnetic navigation-assisted vascular drifting technology, and microvascular EMA guidewires. These fully self-developed platforms will progressively provide greater support for the subsequent research, development, and innovation of Vanroo Medical’s products. In the future, the company will continue to focus on the guidewire application field, integrating more therapeutic functionalities into guidewires.

When discussing his original motivation for starting the business, Xiao Disheng stated, “During my previous work abroad, I observed that original innovation in high-end medical devices, such as those used in vascular intervention, was primarily driven by companies in developed countries, while Chinese domestic enterprises were relatively less involved. However, China’s capabilities in research and development innovation are actually on par with those of foreign counterparts.”“One of the reasons for founding Vanroo was also to demonstrate that China possesses original innovation capabilities ‘from 0 to 1.’”

Xiao Disheng is a serial entrepreneur in the medical device industry, with his research primarily focused on the design, development, and application of vascular interventional medical devices. Having served as a key executive at multiple medical device companies, he has accumulated extensive practical experience. Additionally, Xiao Disheng has assembled a young team at Vanroo Medical(Jiangsu) Technology Co.Ltd with an average age of under 30, leveraging diverse perspectives, open and integrative learning capabilities, and innovative strengths to drive the company’s rapid growth and better adapt to industry and market changes.

In April 2024, Vanroo Medical stood out and was successfully selected in the neurointerventional guiding catheter and support-assist catheter procurement project under the “Beijing-Tianjin-Hebei 3+N” alliance (participating provinces/regions: Anhui, Xinjiang Production and Construction Corps, Guangxi, Guizhou, Liaoning, Qinghai, Sanming, Tibet, Xinjiang, and Yunnan).

In response, Xiao Disheng stated, “I believe that innovative enterprises should not fear volume-based procurement (VBP) policies, but rather face them proactively and participate comprehensively. As VBP has become an integral part of the industry’s business model, it offers dual benefits: on one hand, it enables companies to gain rapid market access, thereby increasing market share and brand visibility; on the other hand, winning bids can build a strong foundation for hospital entry and sales of subsequent new product launches, providing advantageous endorsement.”

Xiao Disheng also acknowledged that while the temporary decline in revenue brought about by volume-based procurement is unavoidable, Vanroo Medical, as an innovative medical device company, is strengthening its global layout and mitigating policy risks associated with volume-based procurement by establishing international collaborations and leveraging its proprietary technologies to assist foreign enterprises in developing vascular interventional products.

In the highly fortified arena of high-end medical devices, cross-disciplinary collaboration is equally critical.In addition to securing numerous patented technologies through continuous innovation, Vanroo Medical has co-authored multiple related papers and books with many physicians. The company also engages in scientific research collaborations with universities such as Tongji University, Nanjing Medical University, Jiangnan University, and Soochow University in fields including brain science and biomaterials. In an interview, Xiao Disheng revealed that the company is currently applying for a national research project, aiming to leverage innovation to help China’s vascular intervention industry reach new heights from a higher-dimensional perspective.

At the end of the interview, Xiao Disheng said, “"Although the process of sifting through thousands of layers is arduous, only after blowing away all the sand does one finally reach the gold."This line from Liu Yuxi’s poetry is the origin of “Vanroo Medical.” Although it is difficult to excel in innovation and persist in it,Yet I remain committed to building Vanroo into a company that integrates the spirit of innovation with the ethos of craftsmanship, showcasing China’s innovative strength to the world.“Going forward, the company will continue to actively expand its portfolio of innovative products, including high-end interventional robotic consumables and optical bio-type guidewires, to provide more comprehensive and higher-quality innovative solutions for the vascular intervention industry, ultimately driving further breakthroughs in China’s high-end medical device sector.”